Supercharge的个人主页 - 老虎社区

Supercharge

暂无个人介绍

IP属地：北京

0关注

0粉丝

0主题

0勋章

03-27

说说你对这篇新闻的看法...

提醒：耶稣受难日、复活节主要市场休市安排一览

2023-09-13

这篇文章不错，转发给大家看看

Moderna aims to prove it's 'more than a COVID company'

2023-08-28

$诺瓦瓦克斯医药(NVAX)$

2022-11-16

2022-11-11

2022-11-11

$箩筐技术(LKCO)$ 。

2022-10-29

$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$

2022-10-07

这篇文章不错，转发给大家看看

@小虎直播:近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉直播回放完整版澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）$Pilbara Minerals Ltd(PLS.AU)$

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4110285110580712","uuid":"4110285110580712","gmtCreate":1647182041558,"gmtModify":1647182041558,"name":"Supercharge","pinyin":"supercharge","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.07","exceedPercentage":"93.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.16","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":288729021751576,"gmtCreate":1711523137304,"gmtModify":1711523138829,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/288729021751576","repostId":"1154680474","repostType":2,"repost":{"id":"1154680474","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1710816980,"share":"https://www.laohu8.com/m/news/1154680474?lang=&edition=full","pubTime":"2024-03-19 10:56","market":"us","language":"zh","title":"提醒：耶稣受难日、复活节主要市场休市安排一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1154680474","media":"老虎资讯综合","summary":"3月29日（周五）为耶稣受难日，3月31日（周日）为复活节，届时，许多有基督教信仰的国家和地区的金融市场都将休市。主耶稣基督惟独吩咐门徒要记念祂的死亡。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。","content":"<html><head></head><body><p>3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。</p><p><strong>具体安排如下：</strong></p><p><strong>美股：</strong> </p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>港股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>A股：</strong></p><p>照常交易</p><p><strong>英股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>澳股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>新加坡市场：</strong></p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>沪股通、深股通、港股通：</strong></p><p>3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。</p><p><strong>背景简介：</strong></p><p>耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。</p><p>复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>提醒：耶稣受难日、复活节主要市场休市安排一览</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n提醒：耶稣受难日、复活节主要市场休市安排一览\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-03-19 10:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。</p><p><strong>具体安排如下：</strong></p><p><strong>美股：</strong> </p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>港股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>A股：</strong></p><p>照常交易</p><p><strong>英股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>澳股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>新加坡市场：</strong></p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>沪股通、深股通、港股通：</strong></p><p>3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。</p><p><strong>背景简介：</strong></p><p>耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。</p><p>复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d39119e26b6941b99faa819a4263ff0f","relate_stocks":{".SPX":"S&P 500 Index","HSI":"恒生指数","HSTECH":"恒生科技指数","HSCEI":"国企指数",".DJI":"道琼斯","HSCCI":"红筹指数",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154680474","content_text":"3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。具体安排如下：美股： 3月29日（周五）休市，4月1日（周一）起照常开市。港股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。A股：照常交易英股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。澳股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。新加坡市场：3月29日（周五）休市，4月1日（周一）起照常开市。沪股通、深股通、港股通：3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。背景简介：耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":219450617716824,"gmtCreate":1694602550322,"gmtModify":1694602551571,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/219450617716824","repostId":"2367551377","repostType":2,"repost":{"id":"2367551377","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1694601180,"share":"https://www.laohu8.com/m/news/2367551377?lang=&edition=full","pubTime":"2023-09-13 18:33","market":"us","language":"en","title":"Moderna aims to prove it's 'more than a COVID company'","url":"https://stock-news.laohu8.com/highlight/detail?id=2367551377","media":"Dow Jones","summary":"As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs. As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc.  on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.\"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch.The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis.The company is expecting an FDA decision on its RSV vaccine for adults a","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna aims to prove it's 'more than a COVID company'\n</p>\n<p>\n  By Eleanor Laise \n</p>\n<p>\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n</p>\n<p>\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n</p>\n<p>\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n</p>\n<p>\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n</p>\n<p>\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n</p>\n<p>\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a>. \n</p>\n<p>\n  Moderna shares are down more than 40% in the year to date, while the S&amp;P 500 SPX has gained 16%. \n</p>\n<p>\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n</p>\n<p>\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&amp;D from 2024 through 2028, the company said. \n</p>\n<p>\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n</p>\n<p>\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n</p>\n<p>\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n</p>\n<p>\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n</p>\n<p>\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n</p>\n<p>\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n</p>\n<p>\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n</p>\n<p>\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n</p>\n<p>\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n</p>\n<p>\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n</p>\n<p>\n  -Eleanor Laise \n</p>\n<p>\n  This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 13, 2023 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna aims to prove it's 'more than a COVID company'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna aims to prove it's 'more than a COVID company'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-09-13 18:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna aims to prove it's 'more than a COVID company'\n</p>\n<p>\n  By Eleanor Laise \n</p>\n<p>\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n</p>\n<p>\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n</p>\n<p>\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n</p>\n<p>\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n</p>\n<p>\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n</p>\n<p>\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a>. \n</p>\n<p>\n  Moderna shares are down more than 40% in the year to date, while the S&amp;P 500 SPX has gained 16%. \n</p>\n<p>\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n</p>\n<p>\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&amp;D from 2024 through 2028, the company said. \n</p>\n<p>\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n</p>\n<p>\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n</p>\n<p>\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n</p>\n<p>\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n</p>\n<p>\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n</p>\n<p>\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n</p>\n<p>\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n</p>\n<p>\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n</p>\n<p>\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n</p>\n<p>\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n</p>\n<p>\n  -Eleanor Laise \n</p>\n<p>\n  This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 13, 2023 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4592":"伊斯兰概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4534":"瑞士信贷持仓","SG9999014542.SGD":"United Income Focus Trust Acc SGD","MRNA":"Moderna, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4501":"段永平概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0861579265.USD":"联博低波幅策略股票基金A","BK4550":"红杉资本持仓","LU0122379950.USD":"贝莱德世界健康科学A2","BK4568":"美国抗疫概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4007":"制药","BK4139":"生物科技","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4588":"碎股","PFE":"辉瑞","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MRK":"默沙东","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4516":"特朗普概念","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2367551377","content_text":"MW Moderna aims to prove it's 'more than a COVID company'\n\n\n  By Eleanor Laise \n\n\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n\n\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. $(MRNA)$ on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n\n\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n\n\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n\n\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n\n\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck & Co. Inc. $(MRK)$. \n\n\n  Moderna shares are down more than 40% in the year to date, while the S&P 500 SPX has gained 16%. \n\n\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n\n\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&D from 2024 through 2028, the company said. \n\n\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n\n\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n\n\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n\n\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n\n\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. $(PFE)$ and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n\n\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n\n\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n\n\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n\n\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n\n\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n\n\n  -Eleanor Laise \n\n\n  This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 13, 2023 06:33 ET (10:33 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":213877706002688,"gmtCreate":1693234382848,"gmtModify":1693234383549,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ &nbsp;</a>","text":"$诺瓦瓦克斯医药(NVAX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/213877706002688","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667199374,"gmtCreate":1668606673699,"gmtModify":1668607006412,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATAT\">$亚朵(ATAT)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/ATAT\">$亚朵(ATAT)$ &nbsp;</a>","text":"$亚朵(ATAT)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667199374","isVote":1,"tweetType":1,"viewCount":94,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":664485051,"gmtCreate":1668178012373,"gmtModify":1668178013176,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NFLX\">$奈飞(NFLX)$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/NFLX\">$奈飞(NFLX)$&nbsp;</a>","text":"$奈飞(NFLX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664485051","isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":664480492,"gmtCreate":1668175344216,"gmtModify":1668175916294,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$ &nbsp;</a>。","listText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$ &nbsp;</a>。","text":"$箩筐技术(LKCO)$ 。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664480492","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":665185646,"gmtCreate":1667047839485,"gmtModify":1667048473301,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASBE.UK\">$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$</a>","listText":"<a href=\"https://laohu8.com/S/ASBE.UK\">$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$</a>","text":"$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/665185646","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":668477753,"gmtCreate":1665138638872,"gmtModify":1665142920338,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4110285110580712","authorIdStr":"4110285110580712"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/668477753","repostId":"661822421","repostType":1,"repost":{"id":661822421,"gmtCreate":1663839705263,"gmtModify":1663874481713,"author":{"id":"4103181690774020","authorId":"4103181690774020","name":"小虎直播","avatar":"https://static.tigerbbs.com/b03dd99cb130298cbe79bcde009e34fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4103181690774020","authorIdStr":"4103181690774020"},"themes":[],"title":"如何在澳股选取最具价值性股票？资源股？农业股？ESG？","htmlText":"\n \n \n  近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉<a href=\"https://ttm.financial/link?target=https%3A%2F%2Flive.byteoc.com%2F9999%2F5606475\" target=\"_blank\">直播回放完整版</a> 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）<a target=\"_blank\" href=\"https://ttm.financial/S/PLS.AU\">$Pilbara Minerals Ltd(PLS.AU)$</a>\n \n","listText":"近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉<a href=\"https://ttm.financial/link?target=https%3A%2F%2Flive.byteoc.com%2F9999%2F5606475\" target=\"_blank\">直播回放完整版</a> 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）<a target=\"_blank\" href=\"https://ttm.financial/S/PLS.AU\">$Pilbara Minerals Ltd(PLS.AU)$</a>","text":"近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉直播回放完整版 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）$Pilbara Minerals Ltd(PLS.AU)$","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/661822421","isVote":1,"tweetType":2,"object":{"id":"17d044867bab490a99c86a2be1405203","tweetId":"661822421","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/e97bc395387702306302828768/v.f30.mp4","poster":"https://static.tigerbbs.com/3142af613e19c3162616373a3183b6b4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":664480492,"gmtCreate":1668175344216,"gmtModify":1668175916294,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$ &nbsp;</a>。","listText":"<a href=\"https://laohu8.com/S/LKCO\">$箩筐技术(LKCO)$ &nbsp;</a>。","text":"$箩筐技术(LKCO)$ 。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664480492","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":288729021751576,"gmtCreate":1711523137304,"gmtModify":1711523138829,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/288729021751576","repostId":"1154680474","repostType":2,"repost":{"id":"1154680474","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1710816980,"share":"https://www.laohu8.com/m/news/1154680474?lang=&edition=full","pubTime":"2024-03-19 10:56","market":"us","language":"zh","title":"提醒：耶稣受难日、复活节主要市场休市安排一览","url":"https://stock-news.laohu8.com/highlight/detail?id=1154680474","media":"老虎资讯综合","summary":"3月29日（周五）为耶稣受难日，3月31日（周日）为复活节，届时，许多有基督教信仰的国家和地区的金融市场都将休市。主耶稣基督惟独吩咐门徒要记念祂的死亡。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。","content":"<html><head></head><body><p>3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。</p><p><strong>具体安排如下：</strong></p><p><strong>美股：</strong> </p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>港股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>A股：</strong></p><p>照常交易</p><p><strong>英股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>澳股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>新加坡市场：</strong></p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>沪股通、深股通、港股通：</strong></p><p>3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。</p><p><strong>背景简介：</strong></p><p>耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。</p><p>复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>提醒：耶稣受难日、复活节主要市场休市安排一览</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n提醒：耶稣受难日、复活节主要市场休市安排一览\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-03-19 10:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。</p><p><strong>具体安排如下：</strong></p><p><strong>美股：</strong> </p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>港股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>A股：</strong></p><p>照常交易</p><p><strong>英股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>澳股：</strong></p><p>3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。</p><p><strong>新加坡市场：</strong></p><p>3月29日（周五）休市，4月1日（周一）起照常开市。</p><p><strong>沪股通、深股通、港股通：</strong></p><p>3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。</p><p><strong>背景简介：</strong></p><p>耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。</p><p>复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d39119e26b6941b99faa819a4263ff0f","relate_stocks":{".SPX":"S&P 500 Index","HSI":"恒生指数","HSTECH":"恒生科技指数","HSCEI":"国企指数",".DJI":"道琼斯","HSCCI":"红筹指数",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154680474","content_text":"3月29日（周五）为耶稣受难日（Good Friday），3月31日（周日）为复活节（Easter），届时，许多有基督教信仰的国家和地区的金融市场都将休市。具体安排如下：美股： 3月29日（周五）休市，4月1日（周一）起照常开市。港股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。A股：照常交易英股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。澳股：3月29日（周五）至4月1日（周一）休市，4月2日（周二）起照常开市。新加坡市场：3月29日（周五）休市，4月1日（周一）起照常开市。沪股通、深股通、港股通：3月29日（周五）至4月1日（周一）关闭，4月2日（周二）起照常开通。背景简介：耶稣受难日：耶稣受难日是基督徒纪念耶稣基督被钉在十字架上受难的日子，为复活节前的那个周五。按《圣经-马太福音》的说法，耶稣基督在十字架上受刑死后3天复活，因而设立复活节。该节是每年春分后首次月圆之后的第一个周日，因此没有固定的公历日期，每年的耶稣受难日自然也没有一个固定的公历日子。复活节：在每年春分月圆之后第一个星期日。是基督教纪念耶稣被钉十字架受死后第三日复活的节日。亦称耶稣复活节、主复活节，天主教亦称耶稣复活瞻礼。","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":219450617716824,"gmtCreate":1694602550322,"gmtModify":1694602551571,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/219450617716824","repostId":"2367551377","repostType":2,"repost":{"id":"2367551377","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1694601180,"share":"https://www.laohu8.com/m/news/2367551377?lang=&edition=full","pubTime":"2023-09-13 18:33","market":"us","language":"en","title":"Moderna aims to prove it's 'more than a COVID company'","url":"https://stock-news.laohu8.com/highlight/detail?id=2367551377","media":"Dow Jones","summary":"As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs. As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc.  on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases.\"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch.The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis.The company is expecting an FDA decision on its RSV vaccine for adults a","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna aims to prove it's 'more than a COVID company'\n</p>\n<p>\n  By Eleanor Laise \n</p>\n<p>\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n</p>\n<p>\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n</p>\n<p>\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n</p>\n<p>\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n</p>\n<p>\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n</p>\n<p>\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a>. \n</p>\n<p>\n  Moderna shares are down more than 40% in the year to date, while the S&amp;P 500 SPX has gained 16%. \n</p>\n<p>\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n</p>\n<p>\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&amp;D from 2024 through 2028, the company said. \n</p>\n<p>\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n</p>\n<p>\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n</p>\n<p>\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n</p>\n<p>\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n</p>\n<p>\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n</p>\n<p>\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n</p>\n<p>\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n</p>\n<p>\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n</p>\n<p>\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n</p>\n<p>\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n</p>\n<p>\n  -Eleanor Laise \n</p>\n<p>\n  This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 13, 2023 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna aims to prove it's 'more than a COVID company'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna aims to prove it's 'more than a COVID company'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-09-13 18:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna aims to prove it's 'more than a COVID company'\n</p>\n<p>\n  By Eleanor Laise \n</p>\n<p>\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n</p>\n<p>\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n</p>\n<p>\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n</p>\n<p>\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n</p>\n<p>\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n</p>\n<p>\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a>. \n</p>\n<p>\n  Moderna shares are down more than 40% in the year to date, while the S&amp;P 500 SPX has gained 16%. \n</p>\n<p>\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n</p>\n<p>\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&amp;D from 2024 through 2028, the company said. \n</p>\n<p>\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n</p>\n<p>\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n</p>\n<p>\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n</p>\n<p>\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n</p>\n<p>\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n</p>\n<p>\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n</p>\n<p>\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n</p>\n<p>\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n</p>\n<p>\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n</p>\n<p>\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n</p>\n<p>\n  -Eleanor Laise \n</p>\n<p>\n  This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 13, 2023 06:33 ET (10:33 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4592":"伊斯兰概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4534":"瑞士信贷持仓","SG9999014542.SGD":"United Income Focus Trust Acc SGD","MRNA":"Moderna, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4501":"段永平概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0861579265.USD":"联博低波幅策略股票基金A","BK4550":"红杉资本持仓","LU0122379950.USD":"贝莱德世界健康科学A2","BK4568":"美国抗疫概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4007":"制药","BK4139":"生物科技","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4588":"碎股","PFE":"辉瑞","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MRK":"默沙东","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4516":"特朗普概念","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2367551377","content_text":"MW Moderna aims to prove it's 'more than a COVID company'\n\n\n  By Eleanor Laise \n\n\n  As COVID vaccine sales fall, Moderna releases positive results from mRNA flu vaccine, adds new development programs \n\n\n  As it looks to expand its horizons beyond COVID-19 vaccines, Moderna Inc. $(MRNA)$ on Wednesday released positive results from a late-stage trial of an mRNA flu vaccine and signaled progress across a range of investigational treatments for cancer and rare, latent and infectious diseases. \n\n\n  \"I hope that people realize that we are more than a COVID company now,\" Moderna Chief Financial Officer Jamey Mock told MarketWatch. The company is looking to launch up to 15 drugs by 2028, he said, which are expected to generate an additional $10 billion to $15 billion in annual revenue about five years after launch. \n\n\n  The new flu-shot data, released ahead of Moderna's research-and-development day Wednesday, showed the company's investigational mRNA vaccine met primary endpoints across four flu strains in a late-stage analysis. \n\n\n  With the late-stage study of the flu vaccine, combined with previous results from COVID and RSV vaccines, \"we are now three-for-three on advancing respiratory-disease programs to positive Phase 3 data,\" Moderna Chief Executive Stephane Bancel said in a statement. \n\n\n  The company said it will release additional data in the fourth quarter on the closely watched personalized cancer vaccine it is developing with Merck & Co. Inc. $(MRK)$. \n\n\n  Moderna shares are down more than 40% in the year to date, while the S&P 500 SPX has gained 16%. \n\n\n  As Moderna faces a drop-off in COVID vaccinations, the company is looking to speed other products to market. Up to four new product launches could come by 2025, the company said. Moderna now has six programs in late-stage development and expects to double the number of programs in Phase 3 studies by 2025. \n\n\n  Up 50 new drug candidates could enter clinical trials over the next five years, and Moderna expects to invest about $25 billion in R&D from 2024 through 2028, the company said. \n\n\n  \"We always knew that if mRNA was going to be successful, it could be very successful across many different therapeutic areas,\" Mock said, \"and I think that's what the data is showing us right now.\" \n\n\n  Moderna last month reported a second-quarter net loss of $1.38 billion, after income of $2.2 billion in the year-earlier period. \n\n\n  Post-pandemic, respiratory products still play a central role in Moderna's plans. The company expects to generate respiratory-product sales of $8 billion to $15 billion in 2027. \n\n\n  Moderna's next-generation, refrigerator-stable COVID vaccine, mRNA-1283, has now completed enrollment of its Phase 3 trial, the company said. \n\n\n  The company is expecting an FDA decision on its RSV vaccine for adults age 60 and older by next April, but it faces stiff competition, as Pfizer Inc. $(PFE)$ and GSK PLC (GSK.LN)already have FDA-approved RSV vaccines for older adults. Mock said the efficacy, safety and ease of use of Moderna's product will help the new shot compete well. \n\n\n  Moderna is also studying various combination respiratory shots, including a combined COVID and flu vaccine and a shot that would combine COVID, flu and RSV protection. Moderna said it expects to release data in the fourth quarter on its next-generation COVID and flu combination vaccine, mRNA-1083. \n\n\n  Beyond respiratory products, Moderna is developing vaccines for cytomegalovirus, Epstein Barr virus, herpes simplex, varicella zoster, norovirus and HIV. \n\n\n  The FDA earlier this week approved Moderna's Spikevax COVID vaccine for ages 12 and above and granted emergency-use authorization for the company's COVID shot for children 6 months through 11 years old. Advisers to the Centers for Disease Control and Prevention on Tuesday recommended Moderna's shot as well as Pfizer's new vaccine for everyone age 6 months and older. \n\n\n  As the vaccines transition to the commercial market, \"we're prepared and ready from a supply perspective,\" Mock said, although demand has lately been tougher to predict. \"We really didn't know what we were getting into this year, and we still don't know exactly what the vaccination rate will actually be, particularly in the United States but also across the globe. And so therefore, we didn't know exactly how much to make.\" The company prepared for higher demand than now appears likely, he said, but \"that's the one hiccup.\" \n\n\n  Moderna's cancer vaccine partnership with Merck is set to expand to additional tumor types. Currently being studied in high-risk melanoma, the companies expect to launch a late-stage trial of the therapy in non-small cell lung cancer later this year. A top investing priority, Mock said, is building out Moderna's manufacturing footprint to ensure the company is ready to serve as many cancer patients as possible. \n\n\n  -Eleanor Laise \n\n\n  This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 13, 2023 06:33 ET (10:33 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":213877706002688,"gmtCreate":1693234382848,"gmtModify":1693234383549,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$ &nbsp;</a>","text":"$诺瓦瓦克斯医药(NVAX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/213877706002688","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667199374,"gmtCreate":1668606673699,"gmtModify":1668607006412,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATAT\">$亚朵(ATAT)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/ATAT\">$亚朵(ATAT)$ &nbsp;</a>","text":"$亚朵(ATAT)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667199374","isVote":1,"tweetType":1,"viewCount":94,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":664485051,"gmtCreate":1668178012373,"gmtModify":1668178013176,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NFLX\">$奈飞(NFLX)$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/NFLX\">$奈飞(NFLX)$&nbsp;</a>","text":"$奈飞(NFLX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664485051","isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":665185646,"gmtCreate":1667047839485,"gmtModify":1667048473301,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASBE.UK\">$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$</a>","listText":"<a href=\"https://laohu8.com/S/ASBE.UK\">$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$</a>","text":"$ASSOCIATED BRITISH ENGINEERING PLC(ASBE.UK)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/665185646","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":668477753,"gmtCreate":1665138638872,"gmtModify":1665142920338,"author":{"id":"4110285110580712","authorId":"4110285110580712","name":"Supercharge","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4110285110580712","idStr":"4110285110580712"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/668477753","repostId":"661822421","repostType":1,"repost":{"id":661822421,"gmtCreate":1663839705263,"gmtModify":1663874481713,"author":{"id":"4103181690774020","authorId":"4103181690774020","name":"小虎直播","avatar":"https://static.tigerbbs.com/b03dd99cb130298cbe79bcde009e34fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4103181690774020","idStr":"4103181690774020"},"themes":[],"title":"如何在澳股选取最具价值性股票？资源股？农业股？ESG？","htmlText":"\n \n \n  近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉<a href=\"https://ttm.financial/link?target=https%3A%2F%2Flive.byteoc.com%2F9999%2F5606475\" target=\"_blank\">直播回放完整版</a> 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）<a target=\"_blank\" href=\"https://ttm.financial/S/PLS.AU\">$Pilbara Minerals Ltd(PLS.AU)$</a>\n \n","listText":"近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉<a href=\"https://ttm.financial/link?target=https%3A%2F%2Flive.byteoc.com%2F9999%2F5606475\" target=\"_blank\">直播回放完整版</a> 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）<a target=\"_blank\" href=\"https://ttm.financial/S/PLS.AU\">$Pilbara Minerals Ltd(PLS.AU)$</a>","text":"近日我们老虎与嘉富诚Richlink联合举办了线上直播讲座，非常荣幸请到郑锦桥，澳洲嘉富诚家族办公室创始人，北大清华客座教授，郑老师来和我们大家做分享，解读美国澳洲加息对股市和经济的影响 下方视频是直播中的一部分，重点谈论了澳州资本市场有哪些独特特点？如何在澳股选取最具价值性股票？欢迎大家一起交流讨论，直播完整版可戳右边点击观看👉直播回放完整版 澳洲嘉富诚成立于2013年，嘉富诚集团全资子公司，目前澳洲嘉富诚主要业务分为三大板块：资产管理、投资银行、财务管理，为投资人和企业提供财富管理和企业咨询服务。（想了解更多投资干货，可以关注嘉富诚官网: www.richlink.com.au，及嘉富诚小助手：richlink_au）$Pilbara Minerals Ltd(PLS.AU)$","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/661822421","isVote":1,"tweetType":2,"object":{"id":"17d044867bab490a99c86a2be1405203","tweetId":"661822421","videoUrl":"https://1254107296.vod2.myqcloud.com/27e1f7ecvodtransgzp1254107296/e97bc395387702306302828768/v.f30.mp4","poster":"https://static.tigerbbs.com/3142af613e19c3162616373a3183b6b4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}